Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 5/20 | 0.35 |
| ▸ | ESRRB | O95718 | 2/20 | 0.35 |
| ▸ | UQCRB | P14927 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870300 | 0.88 | NAAA (0.41) | CTSKNAAACTSLCTSS | |
| SCHEMBL5870628 | 0.83 | GRIA2 (0.35) | CTSKCTSLCTSS | |
| SCHEMBL5870448 | 0.83 | NAAA (0.37) | ALDH1A1MAPTESRRGESRRBCTSK | |
| SCHEMBL5870410 | 0.82 | OPRD1 (0.36) | — | |
| SCHEMBL6972743 | 0.82 | EPHX1 (0.36) | ALDH1A1MAPTESRRGESRRBCTSK | |
| SCHEMBL6753529 | 0.77 | ESRRG (0.34) | ALDH1A1MAPTESRRGESRRBUQCRB | |
| SCHEMBL5870401 | 0.76 | PSMB5 (0.40) | ALDH1A1MAPTCTSKNAAACTSL | |
| SCHEMBL5870460 | 0.74 | ME2 (0.36) | CTSKCTSL | |
| SCHEMBL5870248 | 0.71 | PSMB5 (0.43) | CTSKNAAACTSLCTSS | |
| SCHEMBL5870569 | 0.69 | NAAA (0.46) | CTSKNAAACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | ALDH1A1 2913/4885MAPT 4841/4885ESRRG 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.